ESPR - Esperion Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
37.32
-1.77 (-4.53%)
As of 2:09PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close39.09
Open39.02
Bid37.36 x 900
Ask37.46 x 800
Day's Range37.03 - 39.39
52 Week Range36.06 - 60.99
Volume187,902
Avg. Volume429,584
Market Cap1.014B
Beta (3Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)-2.86
Earnings DateOct 30, 2019 - Nov 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est85.38
Trade prices are not sourced from all markets
  • Does Market Volatility Impact Esperion Therapeutics, Inc.'s (NASDAQ:ESPR) Share Price?
    Simply Wall St.

    Does Market Volatility Impact Esperion Therapeutics, Inc.'s (NASDAQ:ESPR) Share Price?

    If you own shares in Esperion Therapeutics, Inc. (NASDAQ:ESPR) then it's worth thinking about how it contributes to...

  • Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat
    Zacks

    Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat

    Esperion Therapeutics (ESPR) reports mixed second-quarter results.

  • Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates

    Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -8.06% and 5.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results

    ANN ARBOR, Mich., Aug. 08, 2019 -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the second quarter ended.

  • GlobeNewswire

    Esperion to Present at the BTIG Biotechnology Conference

    ANN ARBOR, Mich., Aug. 06, 2019 -- Esperion (NASDAQ:ESPR) today announced that the company will participate in a lipid panel discussion with investors at the BTIG Biotechnology.

  • GuruFocus.com

    Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $197,800 of Shares

    President & CEO of Esperion Therapeutics Inc (30-Year Financial, Insider Trades) Timothy M Mayleben (insider trades) bought 5,000 shares of ESPR on 08/01/2019 at an average price of $39.56 a share. Continue reading...

  • Steven Cohen Charges Into Chiasma
    GuruFocus.com

    Steven Cohen Charges Into Chiasma

    Guru invests in clinical-stage biopharmaceutical company Continue reading...

  • GlobeNewswire

    Esperion to Report Second Quarter 2019 Financial Results August 8, 2019

    ANN ARBOR, Mich., July 30, 2019 -- Esperion (NASDAQ:ESPR) today announced it will report second quarter 2019 financial results on August 8, 2019 before the U.S. financial.

  • A Firm's First Profit Can Mean Big Returns for Investors
    Zacks

    A Firm's First Profit Can Mean Big Returns for Investors

    A Firm's First Profit Can Mean Big Returns for Investors

  • 3 Biotech Stocks Corporate Insiders are Buying
    TipRanks

    3 Biotech Stocks Corporate Insiders are Buying

    Biotech stocks can make compelling investments if investors can pick the right ones. One way to find these winners is to look at the stocks corporate insiders are buying. While an investment decision shouldn’t be made solely on the basis of insider activity, it is an important factor to consider. We are taking a closer look at 3 biotech stocks showing positive insider signals. AVROBIO, Inc. (AVRO)AVRO is a phase 2 clinical-stage gene therapy company that develops treatments for rare diseases such as Fabry Disease, a lysosomal disease that affects the kidneys, heart and skin. Following the announcement on July 19 that it closed its underwritten public offering of 7,475,000 shares of common stock, both the director, Bruce Booth, and Atlas Venture Fund X, L.P. bought over $15 million worth of the stock. Each bought 810,811 shares at an average price of $18.50 per share, with both becoming 24% owners. AVRO plans to use the money generated from the offering for its current Fabry Disease, Gaucher Disease, Cystinosis and Pompe Disease programs as well as to fund further research and development. The purchase comes after top analyst, Difei Yang, reiterated her Buy rating and $28 price target on July 16, suggesting 25% upside. The Mizuho Securities analyst said “AVROBIO has a $4.0 billion total addressable market (TAM). Available clinical data in Fabry disease has shown encouraging results with initial patients treated achieving meaningful improvements in enzyme activity levels and two patients discontinuing enzyme replacement therapy so far (the standard of care).”Another analyst, Debjit Chattopadhyay, also reiterated his Buy rating and $40 price target on July 16. He believes AVRO could soar by as much as 78% over the next twelve months. “While our price target reflects uncertainties stemming from the clinical update from the Fabry program (AVR-RD-01), resulting in: (1) a push out of our launch estimate into 2H-2022, vs. prior 2H-2021; and (2) lower Fabry POS of 25% from 30%, we believe the company is still poised for substantial long-term growth,” the H.C. Wainwright analyst said. The Street is also bullish on AVRO. The stock boasts a ‘Strong Buy’ analyst consensus and $34 average price target, indicating 51% upside potential.Esperion Therapeutics, Inc. (ESPR)ESPR specializes in developing lipid management treatments for patients with high cholesterol. On July 23, BIOTECH TARGET N V, bought 50,000 shares at an average price of $42.65 per share, bringing the total purchase price to over $2 million. This makes Biotech Target a 13% owner of the company.The buy comes after ESPR announced that it entered into a $200 million funding agreement with Oberland Capital on June 26. The agreement is based on net revenues from ESPR’s bempedoic acid and the bempedoic acid/ezetimibe combination tablet sales with $125 million given upfront, $25 million upon FDA approval and $50 million at Esperion’s option after launch.Cowen & Co. analyst, Chris Shibutani, argues that this funding will drive continued growth. On July 18, he maintained his Buy rating and $80 price target. He believes share prices could surge by as much as 92% over the next twelve months. On June 27, analyst, Michael Yee, said, “Esperion's debt financing brings in an immediate $125M, lifting the company's total pro-forma cash to $355M, and gives it flexibility going into 2020\. We view the deal as a non-dilutive, fundamentally good access to cash, that helps shore up Esperion's balance sheet in case of uncertainty and macro risk in 2020.” The Jefferies analyst maintained his Buy rating and $85 price target, suggesting 104% upside potential. ESPR has a ‘Moderate Buy’ analyst consensus, and $85 average price target, indicating 103% upside.Forty Seven, Inc. (FTSV)On July 22, both FTSV’s director, Jeffrey W. Bird, and Lightspeed Venture Partners X, L.P. increased their stakes in the cancer-fighting biotech company formerly known as CD47 Sciences, Inc. Bird purchased 750,000 shares for $6 million while Lightspeed bought 625,000 shares for $5 million at an average price of $8 per share.The purchase fell on the same day as the company’s announcement that it closed its public offering of 10,781,250 shares. The offering included 1,406,250 shares that could be bought by the underwriters. The buy also occurred shortly after news broke of its license agreement with Ono Pharmaceutical. On July 11, it was announced that FTSV would get the exclusive right to develop, manufacture and commercialize the 5F9 monoclonal antibody that targets CD47, a protein that can cause tumors. Analyst Swayampakula Ramakanth believes the licensing agreement could drive share price growth of 130% over the next twelve months. The H.C. Wainwright analyst maintained a Buy rating and $21 price target on July 12. “We derive our price target based on a risk-based NPV (rNPV) analysis of projected 5F9 revenues through 2030 assuming a 12% discount rate and a 3% terminal growth rate. We derive rNPV of $1.1B for 5F9 and add in cash, cash equivalents, and short-term investments of $114M to arrive at a 12-month price target of $20.57 per diluted share, which we round to $21.00,” Ramakanth added. JonesTrading analyst, Soumit Roy, reiterated his Buy rating and $30 price target on June 14. He believes share prices could jump by an impressive 228% over the next twelve months. “We think share prices are going to recover following the success of the company’s anti-PD(L)-1 drugs,” he said. FTSV has a ‘Strong Buy’ analyst consensus and $26 average price target, suggesting 188% upside potential.

  • GuruFocus.com

    Weekly CEO Buys Highlight

    Details the CEO buys this past week for the following companies: AXA Equitable Holdings, Liberty Latin America, Karuna Therapeutics, Esperion Therapeutics and Altus Midstream

  • GlobeNewswire

    Esperion and Oberland Capital Announce $200 Million Funding Agreement

    Esperion (ESPR) and an investor group led by Oberland Capital Management LLC (Oberland Capital) today announced a $200 million capped, tiered, revenue-based funding agreement on net revenues of bempedoic acid and the bempedoic acid / ezetimibe combination tablet.  Bempedoic acid and the bempedoic acid / ezetimibe combination tablet were developed as complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C) who require additional LDL-C lowering despite the use of currently accessible therapies. “We are very excited to collaborate with the team at Oberland Capital given their experience and expertise in the industry,” said Rick Bartram, chief financial officer of Esperion.

  • Have Insiders Been Buying Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares This Year?
    Simply Wall St.

    Have Insiders Been Buying Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares This Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

  • Esperion Therapeutics (ESPR) Down 5.6% Since Last Earnings Report: Can It Rebound?
    Zacks

    Esperion Therapeutics (ESPR) Down 5.6% Since Last Earnings Report: Can It Rebound?

    Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire

    Esperion Announces the Appointment of Tracy M. Woody to Board of Directors

    Esperion (ESPR) today announced the appointment of Tracy M. Woody as a Class I director, with a term expiring at the 2020 meeting of stockholders. "On behalf of the Lipid Management team and our directors, I am very pleased to welcome Tracy to the Esperion board.

  • Biotech Stocks Clobbered As Two Slammed With Sell Ratings
    Investor's Business Daily

    Biotech Stocks Clobbered As Two Slammed With Sell Ratings

    Clovis Oncology and Esperion Therapeutics stocks skidded Wednesday after an analyst downgraded the biotech companies to sell ratings amid rising competition in their respective markets.

  • GlobeNewswire

    Esperion to Participate in Upcoming Investor Conferences

    A live audio webcast of the Jefferies event can be accessed on the investor relations section of the Esperion website at www.esperion.com. Bempedoic acid is our lead, non-statin, complementary, orally available, once-daily, LDL-C lowering therapy. With a targeted mechanism of action, bempedoic acid is a first-in-class, ATP Citrate Lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers LDL-C by up-regulating the LDL receptor.

  • MoneyShow

    Esperion Aims for the First Approved Non-Statin Cholesterol Reducer

    The FDA has accepted both New Drug Applications from Esperion (ESPR) for bempedoic acid and the bempedoic acid/ezetimibe combination tablet for filing and regulatory review, reports John McCamant, biotech specialist and editor of The Medical Technology Stock Letter.

  • MoneyShow

    Esperion Gets a Go-Ahead from the FDA

    Esperion Therapeutics (ESPR) has reported that the FDA has accepted both New Drug Applications for bempedoic acid and the bempedoic acid/ezetimibe combination tablet for filing and regulatory review, asserts John McCamant, biotech expert and editor of The Medical Technology Stock Letter.

  • Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Surpass Estimates
    Zacks

    Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Surpass Estimates

    Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 132.58% and 53.20%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    Esperion Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the Ann Arbor, Michigan-based company said it had net income of $3.07. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

  • GlobeNewswire

    Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results

    ANN ARBOR, Mich., May 08, 2019 -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the first quarter ended.

  • GlobeNewswire

    Esperion to Host Analyst and Investor Day Event on May 30

    ANN ARBOR, Mich., May 07, 2019 -- Esperion (NASDAQ:ESPR) today announced that the company will host an analyst and investor day on Thursday, May 30, 2019, beginning at 9:00.

  • A Single Rival Caused 2 Biopharma Stocks To Slip — Here's Why
    Investor's Business Daily

    A Single Rival Caused 2 Biopharma Stocks To Slip — Here's Why

    Esperion popped Monday after the Food and Drug Administration accepted its applications for a pair of cholesterol treatments called bempedoic acid and bempedoic acid plus ezetimibe.